While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

Mounjaro is one of the bestselling weight loss drugs. See what your options are if you want to invest in Mounjaro stock.

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both have witnessed rapid demand despite being on the market for less than ...

Quarterly sales for blockbuster diabetes drug Mounjaro totaled more than $3 billion. (George Frey/Reuters) Eli Lilly shares jumped after the drugmaker reported earnings that trumped analyst ...

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes ...

Eli Lilly sues telemedicine companies for selling untested, unapproved drugs. The company accuses them of deceiving consumers about 'untested, unapproved drugs.' ...